Closing arguments begin in Neurontin US court case

Bloomberg reported that closing arguments began Tuesday in a US federal court in a lawsuit brought by Kaiser Foundation Health Plan and Kaiser Foundation Hospitals that claims that Pfizer illegally promoted Neurontin for unapproved uses.

During the trial, Kaiser alleged that Pfizer misled the insurer into believing that Neurontin, which received FDA approval in 1993 as a treatment for epilepsy, was also effective for migraines, bipolar disorder, neuropathic pain and other conditions, and prescribed the drug in doses larger than the maximum approved by the FDA. Kaiser alleges that it could have saved money spent on off-label Neurontin prescriptions if Pfizer hadn’t misrepresented the drug.

Pfizer lawyers countered that Kaiser permitted its doctors to prescribe Neurontin for off-label conditions, even after the insurer filed the suit in 2005, and that their website continues to list Neurontin as a drug for neuropathic pain.

To read more Top Story articles, click here.